All In MedTech

FDA Clearance Tracker · P180035-S032

MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 17, 2025

Approved

Time to decision

75 days

Received Oct 3, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P180035-S032
Device name
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
Applicant location
Pleasanton, CA
Received
Oct 3, 2025
Decided
Dec 17, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P180035

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code QIT

FDA's approval statement

As written in FDA's record.

revised protocol for the post-approval study (PAS001)

Source documents

Other decisions for CooperVision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.